Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #11694
Ace Report Cover Spine

No increase in adverse events with liposomal bupivacaine vs placebo in elective lumbar spine surgery

Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A

Can Liposomal Bupivacaine Be Safely Utilized in Elective Spine Surgery?

Global Spine J. 2019 Apr; 9(2): 133–137.

Contributing Authors: L Brown E Koh M Shasti T Weir S Koenig I Yousaf O Yousaf O Tannous K Banagan D Gelb S Ludwig

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


59 patients with degenerative spondylosis scheduled for elective open posterior lumbar decompression and instrumented fusion were randomized to receive a pre-wound closure injection of liposomal bupivacaine (266mg) or placebo for the treatment of post-operative pain. The primary outcome of interest was the incidence of adverse events. The secondary outcome of interest was the length of hospital st...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.